NZ HERALD: The Herald’s medical reporter, Martin Johnston, has written a balanced account on where we are with the great PSA debate. READ MORE>
Posts Tagged ‘PROSTATE CANCER’
Posted in SELECT COMMITTEE INQUIRY, tagged Health Select Committee, NZ, NZ Parliament, prostate, PROSTATE CANCER, prostate detection, Prostate inquiry, prostate report, PSA on July 27, 2011 | 2 Comments »
Posted in PSA tests, tagged blood test, blood tests, medical checkups, prostablog, prostate, prostate blog, PROSTATE CANCER, prostate-specific antigen, PSA, PSA test, Screening debate on April 6, 2011 | 1 Comment »
PROSTABLOG NZ: The PSA test may get a bad rap from epidemiologists and the Ministry of Health, but so far as I’m concerned it’s a winner.
It’s a reliable post-treatment indicator of whether your prostate cancer is coming back or not, and I’ve just had my two-year test – and it remains undetectable.
That’s very good news, so far as I can discern. My reading of things prostate tells me the two-year mark is a crucial one, a time when recurrence is most likely to rear its unwelcome head.
That doesn’t mean I’m cured. There’s a long way to go before that marker, perhaps a decade.
The only thing I’m not sure about is the fact my PSA never registered much (let alone any change) prior to my diagnosis in 2008.
Does that mean post-surgery PSA tests won’t work on me either.
Nah, let’s not dwell on it.
Posted in Uncategorized, tagged blood test, blood tests, cancer screening, catheter, digital diagnosis, digital examination, Health Select Committee, Mark von Dadleszen, mass screening for prostate, medical checkups, Ministry of Health, NZ Health Select Committee, NZ Parliamentary inquiry into prostate cancer, Paul Hutchison, prostablog, prostate, PROSTATE CANCER, Prostate Cancer Foundation of NZ, prostate cancer inquiry, prostate cancer screening, prostate testing, prostate treatment debate, prostate-specific antigen, PSA, PSA test, Screening debate on April 2, 2011 | 3 Comments »
PROSTABLOG NZ: Exact meaning of the word “encourage” will be pivotal in the continuing New Zealand saga on how best to prevent prostate cancer.
“We will be encouraging men to go to their GPs to discuss options…including whether or not they should have a PSA test,” says the chairman of Parliament’s inquiry into prostate cancer, Paul Hutchison, in today’s Dominion Post newspaper (see below).
In the same story, his statement is welcomed by Prostate Cancer Foundation of NZ president Mark von Dadelszen: “…we would certainly applaud that move.”
What they both mean by the term “encourage” is about to become the focus of a debate that has churned around in global prostate cancer politics since PSA testing became commonly available in the early 1990s.
First question: how does “encouraging” men to be tested differ from a national screening programme (which Hutchison signals will be rejected in the inquiry report due in a matter of weeks)?
A national screening programme presumably involves the Ministry of Health spending millions promoting tests to the general populace, as it does with breast and cervical cancers.
Such programmes “encourage” people to get along to their doctor and have the tests.
How will men be encouraged? Not with a lot of advertising, it seems.
So how, exactly?
By training barbers to spread the word to their clients, as has been tried in the US?
By sending doctors into communities to talk about risks and options, as the Foundation did last year when it flew a team to the Chathams?
By leaving it to the Foundation to publicise the disease and urge men to act, as happens now?
Whatever approach the Health Select Committee is about to recommend, it needs to deal with a mammoth in the waiting rooms – the Ministry of Health instruction to GPs that they must not raise the topic of PSA and rectal examination until the patient does or unless they spot symptoms obviously related to what is often a symptomless disease.
This is the real crux of the dilemma the Select Committee has presumably been wrangling with since its first public hearings in September, 2009.
What instruction will it recommend the Government give to the Ministry, whose staff and advisers adamantly oppose any widening of the availability of PSA testing?
Up to now, men have been the subject of a mild but just as deadly form of Russian roulette when it comes to being diagnosed.
Take my own case.
Over the past 30 years, I’ve been under the care of four GPs. The first never mentioned prostate cancer (to be fair, I was under 50); the second (mid 1990s) refused to consider PSA tests because to him they were unproven; the third insisted on it without my bidding; and my current one responded readily to my request for tests (saying Ministry instructions forbade him raising the matter unless I spoke up first!).
Anecdotal evidence suggests the Ministry’s obfuscation is becoming increasingly irrelevant – for some people, anyway.
The Foundation’s awareness campaigns have been effective, if I judge by the number of male acquaintances now being diagnosed early and successfully treated.
However, I suspect there are dangerous class factors at play here.
Me and my mates are okay because we have been blessed by education, higher socio-economic status, media awareness and access to health provision.
I fear for those who don’t. The Ministry’s stubbornness condemns them to an uncertain fate.
National prostate screening rejected
Dominion Post April 2, 2011
A PARLIAMENTARY inquiry into prostate cancer screening will not be recommending a national screening programme despite pressure from cancer survivors to do so.
The Prostate Cancer Foundation has backed the committee’s approach, but a former patient says the decision is disappointing.
Health select committee chairman Paul Hutchison said the inquiry, which has been running since May 2009, was not due to report back for another few weeks, but when it did, it would not advocate screening.
There was still controversy over whether blood tests for prostate-specific antigens led to fewer prostate cancer deaths, he said.
Heightened levels of prostate specific antigen – PSA – can indicate the presence of prostate cancer. However, early detection can result in aggressive and unpleasant treatment of tumours that would never have grown or created ill-health.
The inquiry has heard from a huge number of prostate cancer survivors, many of whom asked for a screening programme for all men aged 50 and older.
Dr Hutchison could not go into detail about the committee’s findings but said there were two main conclusions.
‘‘We will not be recommending a PSA screening programme. However, we will be encouraging men to go to their GPs to discuss options … including whether or not they should have a PSA test.
‘‘Those are the two points that are loud and clear.’’
Prostate Cancer Foundation president Mark von Dadelszen said the organisation did not support a national screening programme because of ‘‘issues’’ with the PSA test.
‘What it does advocate is that men should be encouraged to have screening tests . . . we would certainly applaud that move.’’
Napier farmer Duncan McLean, who has just got the all-clear five years after being diagnosed with prostate cancer, said encouragement was good but the committee should recommend a full screening programme.
Mr McLean, 57, had his prostate gland removed in 2006 after several years of increasingly high PSA readings, followed by a biopsy that confirmed the cancer.
‘‘PSA testing is essential. I’m alive today because of it. It’s really disappointing they’re not [recommending screening].’’
Fears about over-treatment were ‘‘bollocks’’, he said. ‘‘You don’t leap in and go under the surgeon’s knife – I was monitored for three years before I had surgery.’’
International research on the matter is split, with several largescale studies under way.
The results of a 20-year Swedish study, published yesterday in the British Medical Journal, found screening did not significantly reduce prostate cancer deaths but the risk of overdetection and unnecessary treatment was considerable.
However, another Swedish study found death from prostate cancer more than halved among men who were screened.
Posted in Erectile function, Incontinence, Radical prostatectomy, Shorter penis, tagged blood tests, catheter, Erectile function, Incontinence, prostablog, prostate, prostate blog, PROSTATE CANCER, prostate cancer treatments, prostate treatment, prostate-specific antigen, prostatectomy, PSA, PSA test, quality of life, Radical prostatectomy, surgery, Urination on January 14, 2011 | 4 Comments »
But I’m not getting cocky just yet (forgive the pun).
From what I’ve read about prostate cancer treatment, if the cancer bug has got out of the organ during/after a prostatectomy, there’s a good chance the first signs will come two years after the operation.
My two-year anniversary comes up in a couple of months – so wish me luck.
It’s interesting how long it takes to fully recover from the surgery’s effects.
My scar is virtually gone and I’ve felt fit for ages.
There’s no incontinence. I haven’t done the pelvic floor exercises for more than a year, but there’s never any problem with not being able to hold it in, even when I’m busting.
Not that I put myself in the busting mode if I can avoid it.
So, hey, no regrets and no real worries. I’m bloody lucky.
Well, there is one worry – the number of friends and people I know who have been diagnosed. Talk about an epidemic.
And I wonder if the NZ Parliamentary Health Select Committee will ever get round to reporting back on its prostate cancer inquiry…
Posted in Chemotherapy, tagged catheter, chemotherapy sessions, Health Minister Tony Ryall, NZ cancer treatment stats, prostablog, prostate, prostate blog, PROSTATE CANCER, prostate cancer treatments, prostate treatment on October 5, 2010 | Leave a Comment »
Posted in New tests, tagged biological signals, Biomarkers, cancer research, catheter, diagnostic tests, lab test, Oxford Gene Technology, prostablog, prostate, prostate blog, PROSTATE CANCER, prostate cancer screening, REUTERS, Screening debate on October 5, 2010 | Leave a Comment »
REUTERS: British scientists say they have developed a lab test that can accurately distinguish prostate cancer from healthy tissue and other prostate conditions. READ MORE>
Researchers at a genetics and diagnostics firm Oxford Gene Technology say the set of biological signals, or biomarkers, they have identified was able to distinguish healthy tissue and benign prostate disease from prostate cancer with 90 percent accuracy in initial laboratory sample tests.
A full test for use in doctors’ clinics is likely to be at least five years off, they said, but their pilot study testing around 130 samples showed encouraging results in a disease area where more accurate diagnostic tests are sorely needed.